Older adults continue to face high risks from vaccine preventable diseases, yet coverage rates for influenza, pneumococcal disease and other respiratory infections remain suboptimal in many Member States.

Immune imprinting, in which prior antigenic exposures biases recall toward dominant epitopes, constrains the breadth and durability of influenza vaccine protection.

‘A public health call to action: Europe needs a coordinated approach to ensure vaccination coverage at all stages of life, writes Professor Stefania Maggi.

Vaccine-induced immune thrombocytopenia and thrombosis (VITT) is a rare prothrombotic complication that occurs after adenoviral vector–based vaccination against coronavirus disease 2019.

Abundant evidence has correlated influenza infection with cardiovascular disease, yet mechanisms linking infection with the heart remain poorly understood.

A Seamless Approach to Protection Across All Ages and Risk Groups

The International Longevity Centre UK (ILCUK) report highlights how Europe's aging population faces increasing health challenges due to immunosenescence, which reduces vaccine effectiveness and increases vulnerability to disease.

In self‐controlled case series studies, laboratory‐confirmed influenza infection was associated with an elevated risk of acute myocardial infarction and stroke during the first 1 month.